Frazier Life Sciences Acquisition Corp. II
Frazier Life Sciences Acquisition Corp. II is based in Palo Alto, California, and seeks to combine with one or more businesses. It may pursue a transaction structured as a merger, acquisition, share exchange, reorganization, or another similar business combination.
No enriched coverage for $FLSC in the last 7 days.
No SEC Form 4 filings for $FLSC in the last 30 days.
See all $FLSC insider activity →Frazier Life Sciences Acquisition II raised $78 million, including $75 million from a 7.5 million share IPO at $10 each and $3 million from private placement. The funds were placed in a trust account. The company has not yet identified a target for business combination, according to its SEC filing.
Frazier Life Sciences Holdings II LLC disclosed a 20.5% stake in Frazier Life Sciences Acquisition Corp. II, including 300,000 Class A shares. The sponsor may buy or sell more shares and consider strategic moves, but has no specific plans. The firm focuses on healthcare and biotech investments.
The IPO market saw few listings, with biotech companies City Therapeutics (CTY) and Iambic Therapeutics (IAM) raising $200M and $150M respectively. CTY priced at $18.00, opened at $23.00, and saw a 28% debut increase. IAM priced at $16.00 and is currently trading at $23.87. Anthropic (ANTP) is expected to IPO soon, but investors may seek lower valuation. Fed rate hikes and macro caution may impact IPO activity.
Recent FLSC coverage spans corporate actions, ipo and financial news.
The capital raise adds cash to the SPAC but funds are locked in trust, limiting immediate price impact.
The large insider stake may be interpreted as confidence in the SPAC, prompting investors to reassess valuation.
SPAC debut can attract speculative flows, but valuation and redemption dynamics will dominate after initial pricing.
The filing is a fresh insider open-market purchase, which can be read as confidence but is not a fundamental change by itself.
Newly disclosed IPO pricing and expected close date create immediate float and liquidity expectations for FLSC, with near-term trading focus on first-day positioning.
AlphAI scores every news story that mentions FLSC with an AI model for sentiment and relevance, and aggregates insider trades from Frazier Life Sciences Acquisition Corp. II's SEC EDGAR Form 4 filings. Figures refresh continuously.
Frazier Life Sciences Acquisition II raised $78 million, including $75 million from a 7.5 million share IPO at $10 each and $3 million from private placement. The funds were placed in a trust account. The company has not yet identified a target for business combination, according to its SEC filing.
Frazier Life Sciences Holdings II LLC disclosed a 20.5% stake in Frazier Life Sciences Acquisition Corp. II, including 300,000 Class A shares. The sponsor may buy or sell more shares and consider strategic moves, but has no specific plans. The firm focuses on healthcare and biotech investments.
The IPO market saw few listings, with biotech companies City Therapeutics (CTY) and Iambic Therapeutics (IAM) raising $200M and $150M respectively. CTY priced at $18.00, opened at $23.00, and saw a 28% debut increase. IAM priced at $16.00 and is currently trading at $23.87. Anthropic (ANTP) is expected to IPO soon, but investors may seek lower valuation. Fed rate hikes and macro caution may impact IPO activity.
Cha Albert (Chief Executive Officer) purchased 300,000 indirectly-held shares of Frazier Life Sciences Acquisition Corp. II (FLSC) at $10.00 ($3.00M total) on 2026-10-15. Filed jointly with Frazier Life Sciences Holdings II LLC (10% owner), Frazier Life Sciences Public Fund, L.P. (10% owner), FHMLSP, L.P. (10% owner) and FHMLSP, L.L.C. (10% owner).
Frazier Life Sciences Acquisition Corp. II (FLSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering Palo Alto, CA, October 13, 2026 – Frazier Life Sciences Acquisition Corp. II (the “Company”), a special purpose acquisition company, announced today that it priced its
Frazier Life Sciences Acquisition Corp. II raised $75m in its IPO, issuing 7.5m shares at $10 each. The SPAC began trading on Nasdaq under the ticker FLSC. The company, led by CEO Albert Cha, aims to merge with a biotechnology business. Jefferies managed the offering, which was approved by the SEC.
